Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antimicrobial resistance in Helicobacter pylori (H. pylori) is a significant global health challenge.
• The World Health Organization has prioritized clarithromycin-resistant H. pylori due to increasing resistance rates worldwide.
• Current treatment guidelines recommend quadruple therapy, but concerns exist regarding the promotion of further antimicrobial resistance.

Purpose of the Study:

• To explore novel therapeutic strategies for H. pylori eradication.
• To identify treatment regimens that minimize the development of future antimicrobial resistance.
• To evaluate the potential of dual therapy with vonoprazan and amoxicillin as a breakthrough treatment.

Main Methods:

• Review of current literature on H. pylori resistance patterns and treatment guidelines.
• Analysis of the proposed dual-therapy regimen (vonoprazan and amoxicillin).
• Assessment of the impact of vonoprazan on gastric acid secretion and its potential role in enhancing eradication and reducing resistance.

Main Results:

• Increasing resistance to clarithromycin, metronidazole, and fluoroquinolones necessitates alternative H. pylori treatments.
• Quadruple therapies, while effective, may inadvertently contribute to future antimicrobial resistance.
• Dual therapy with vonoprazan and amoxicillin shows promise for satisfactory H. pylori eradication rates.
• This regimen may reduce the risk of promoting antimicrobial resistance through single antibiotic use and vonoprazan's potent acid suppression.

Conclusions:

• A new strategy is needed to combat H. pylori resistance and reduce antibiotic usage.
• Dual therapy with vonoprazan and amoxicillin presents a potential breakthrough for H. pylori eradication.
• This approach could effectively treat H. pylori infection while mitigating the development of future antimicrobial resistance.